A single protein signalling pathway, active in roughly 85% of colorectal cancer patients, appears to simultaneously drive tumour growth and block the immune system from attacking it. This matters because colorectal cancer is one of the most common cancers in the UK, and current immunotherapies often fail in patients whose tumours have high levels of WNT signalling. The researcher suspects that the same WNT-driven immune suppression that occurs in cancer also happens during normal intestinal repair after injury—meaning the mechanism might be a general feature of rapidly dividing gut tissue, not just a cancer-specific quirk. The project will map immune cell behaviour in regenerating mouse intestines using advanced imaging and single-cell techniques, then test whether blocking WNT signalling restores immune activity. If the mechanism is conserved, drugs that temporarily dampen WNT signalling could make WNT-driven tumours vulnerable to immunotherapy without causing widespread toxicity. This is fundamental science with a clear translational target: understanding how a common cancer evades the immune system could open new treatment options for patients who currently have few.
View original technical description
WNT signaling is responsible for regulating proliferation and differentiation of intestinal stem cells (ISCs). The importance of this pathway is highlighted in injury induced regeneration, where pharmalogical inhibition of WNT prevents ISC-dependent regeneration of the intestine. However, aberrant WNT activation is a hallmark of colorectal cancer (CRC), and found in ~85% of patients. Recently, a link has been discovered between hyperactivation of WNT and poor infiltration of cytotoxic T lymphocytes (CTL) in both human and mouse CRC. Consistently, WNT-mediated CTLs exclusion has also been found in WNT-high crypts in normal intestine and WNT activating regenerating crypts, suggesting that the WNT- mediated CTL exclusion is possibly a conserved mechanism in normal and regenerating intestinal crypts, as well as in cancer. Therefore, I aim to investigate the relationship between WNT activation and immunosuppression in intestinal regeneration and explore if there is a conserved or context-dependent mechanism between cancer and regeneration. Using the cutting-edge techniques CITE-seq, imaging mass cytometry (IMC) and high- dimensional flow cytometry, I will spatiotemporally characterize the regenerating intestines upon targeted whole-intestine irradiation. This will be paired with immunomodulation models and pharmalogical inhibition of WNT upon irradiation induced regeneration to determine whether WNT dependent immunomodulation is required for intestinal regeneration. Finally, I will use endoscopy-guided orthotopic transplantation of WNT-high vs WNT-low tumor organoids to determine whether WNT-dependent immunomodulation is conserved between intestinal regeneration and cancer. Ultimately, these results will provide novel insights into immune cell dynamics upon regeneration, as well as for the development of tumor-specific therapies in WNT-activated CRCs with minimal toxicity.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know